Detail page

Knowledge Web

Person

Johannes Gojo (1985-)

Arzt

Name	Johannes Gojo
Time	1985- (Date of birth and death)
Place	Wien (Wirkungsort) Österreich
Gender	männlich
Academic degree	Univ.-Prof. Dr.med. Dr.scient.med.
Profession	Arzt (characteristic profession) Kinderarzt Hochschullehrer
Variant	Johannes Salomon Gojo J. Gojo J. S. Gojo
Related	Universitäts-Klinik für Kinder- und Jugendheilkunde (Wien)
Source	https://www.meduniwien.ac.at/web/en/forschung/researcher-profiles/researcher-profiles/detail/?res=johannes_gojo&cHash=9a029f5fee6edc1f381982264e5bd9f4 (Stand: 23.09.2024)
Record type	Person
GND-Identifier	1217281959
Record ID	1217281959
Involved in show all The telovelar approach for fourth ventricular tumors in children: is removal of the posterior arch of C1 necessary? Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology Bridging the gap: A quality improvement project to implement psychosocial care standards into clinical practice in pediatric oncology Clinical applicability of miR517a detection in liquid biopsies of ETMR patients Placement of EVD in pediatric posterior fossa tumors: safe and efficient or old-fashioned? The Vienna experience Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification A whole‐genome scan for Artemisinin cytotoxicity reveals a novel therapy for human brain tumors The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum Innovative therapy concepts for pediatric brain tumors Targeting fibroblast growth factor receptors to combat aggressive ependymoma PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma New brain tumor entities emerge from molecular classification of CNS-PNETs

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Johannes Gojo (1985-)

The telovelar approach for fourth ventricular tumors in children: is removal of the posterior arch of C1 necessary?

Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors

Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology

Bridging the gap: A quality improvement project to implement psychosocial care standards into clinical practice in pediatric oncology

Clinical applicability of miR517a detection in liquid biopsies of ETMR patients

Placement of EVD in pediatric posterior fossa tumors: safe and efficient or old-fashioned? The Vienna experience

Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification

A whole‐genome scan for Artemisinin cytotoxicity reveals a novel therapy for human brain tumors

The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location

Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification

Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness

Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors

PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

Innovative therapy concepts for pediatric brain tumors

Targeting fibroblast growth factor receptors to combat aggressive ependymoma

PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas

Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies

Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma

New brain tumor entities emerge from molecular classification of CNS-PNETs